Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pierre Fabre Pharma GmbH
With
Winicker Norimed GmbH
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Written informed consent of the patient with regard to the pseudonymized documentation and processing of his/her disease data
Legally capable male or female NSCLC patient or legally capable female MBC patient; in both situations: ≥ 18 years of age (no upper limit)
Presence of any of the following two tumor entities:
* Advanced NSCLC (stage III or IV)
* Anthracycline- and taxane-resistant MBC (stage IV) in women
Planned systemic chemotherapy and planned regimen with oral vinorelbine in any palliative setting (decision on treatment must have been made before inclusion in this study); included treatments:
* Monotherapy or any combination therapy with oral vinorelbine
* Inclusion of patients with hybrid-treatment involving i.v. and oral vinorelbine in one treatment cycle is allowed
You may not be if
Presence of any contraindication with regard to oral vinorelbine treatment (and with regard to i.v. vinorelbine in case of hybrid-treatment) according to the respective Summary of Product Characteristics (SmPC)
Oral vinorelbine based palliative treatment already ongoing or planned oral vinorelbine starting dose of \>60 mg/m2
Presence of a Eastern Cooperative Oncology Group (ECOG) performance status (PS) \> 2
Simultaneous participation in an interventional clinical trial
